The global market for biosimilars is expected to witness significant growth in the coming years. According to a report by MarketsandMarkets, the market is expected to reach a value of $74.1 billion by 2025, at a compound annual growth rate of 24.5% from 2020 to 2025.
The increasing adoption of biosimilars is driven by factors such as the expiry of patents on innovator products, the increasing prevalence of chronic diseases, and the growing focus on cost containment in the healthcare sector. Biosimilars offer a cost-effective alternative to innovator products, which can help to reduce healthcare costs and increase access to treatment for patients.
The Asia-Pacific region is expected to witness the highest growth in the biosimilars market, due to factors such as the increasing prevalence of chronic diseases, the growing focus on cost containment, and the expanding healthcare infrastructure in the region.
In addition to the growth of the biosimilars market, the overall monoclonal antibody market is also expected to witness significant growth. According to a report by Research and Markets, the global mAb market is expected to reach a value of $250.5 billion by 2025, at a compound annual growth rate of 10.6% from 2020 to 2025.
The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is a key factor driving the growth of the mAb market. The development of new and innovative mAb products, as well as the increasing adoption of biosimilars, is also contributing to the growth of the market.
In conclusion, the growth of the biosimilars market and the overall mAb market is expected to continue in the coming years, driven by factors such as the increasing prevalence of chronic diseases, the expiry of patents on innovator products, and the growing focus on cost containment in the healthcare sector. This growth is expected to result in the development of new and innovative mAb products, as well as increased access to treatment for patients.